Remove Marketing Remove Medical Remove Pharmaceutical
article thumbnail

There Are So Many Skincare Lines– Is One Better Than Another?

Renee Rouleau

In today’s saturated skincare market, it can be overwhelming to navigate through the countless options available. Pharmaceutical and Medical Advancements Ingredients that have been traditionally used for non-skincare purposes are now finding their way into the beauty industry. This is a fair point.

Skincare 195
article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. We will, for sure, have new medications for chronic urticaria.”

article thumbnail

Warts and All: Verrica and Torii Team Up to Fund Global Phase 3 Trial of YCANTH for Common Warts

The Dermatology Digest

Verrica Pharmaceuticals Inc. has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. seeking Food and Drug Administration approval for the use of YCANTH for the treatment of common warts, but may also be utilized by Verrica to seek future marketing authorizations in territories outside the U.S.

article thumbnail

Multi-Mechanical Therapies with Topicals For Age Management

Lipgloss and Aftershave

Phyllis Hsieh is the visionary behind Conrex Pharmaceutical Corp. Under her leadership, SESHA has expanded into a diverse range of over 70 therapeutic products, now available across Asia, Europe, and other global markets. The Permeation Enhancement Technology is FDA-approved in pharmaceuticals.

article thumbnail

Weight-loss stocks soar up to 15% after obesity-drug study shows an added benefit that may be a ‘huge win’ for future sales

Aesthetics Advisor

. — better known as Weight Watchers — which bought a telemedicine firm that prescribes obesity medications earlier this year, soared 13%. Analysts saw the benefit extending the market for Wegovy as well as Lilly’s Mounjaro and possibly removing an obstacle in insurance reimbursement. also gained — rising 9.0% respectively.

Sales 36
article thumbnail

A Glimpse Inside the Lichen Planus Pipeline

The Dermatology Digest

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Similarly, Incyte and AFYX Therapeutics are developing new therapeutics for lichen planus.

article thumbnail

Sun Pharma Launches WINLEVI CTV Ad Campaign to Demystify Sebum With Dr. Sandra Lee

The Dermatology Digest

Sun Pharmaceutical Industries, Inc. The parents misunderstand this unfamiliar word as inappropriate for family dinner conversation but quickly learn from Dr. Lee that it is a medical term that does not need to be censored. Food and Drug Administration-approved topical acne treatment available in the U.S.

Sebum 36